0836 GMT - U.K. pharma could have some share-price volatility but the long-term outlook shouldn't be affected by U.S. President Trump's imposed tariffs on global imports that currently exempt drugs and vaccines, Shore Capital analyst Sean Conroy says in a note. The longer-term revenue targets for British pharma companies GSK and AstraZeneca extend beyond the remaining term of Trump and their fundamentals remain robust as populations are getting older and sicker, the analyst says. "Pharma often finds itself in the firing line when it comes to U.S. politics--given the prominence of drug prices on the U.S. political agenda and news cycle--however, more often than not there is a material difference between traveling and arriving, with the impact realized often far less draconian than initially feared," he says. GSK and AstraZeneca are both up 1.5% and 1.6%, respectively. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 03, 2025 04:36 ET (08:36 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.